Adversaries Continue Cyberattack Onslaught with Greater Precision and Innovative Attack Methods according to 1H2022 NETSCOUT DDoS Threat Intelligence Report
27.9.2022 13:05:00 EEST | Business Wire | Press release
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) today announced findings from its 1H2022 DDoS Threat Intelligence Report. The findings demonstrate how sophisticated cybercriminals have become at bypassing defenses with new DDoS attack vectors and successful methodologies.
"By constantly innovating and adapting, attackers are designing new, more effective DDoS attack vectors or doubling down on existing effective methodologies," said Richard Hummel, threat intelligence lead, NETSCOUT. "In the first half of 2022, attackers conducted more pre-attack reconnaissance, exercised a new attack vector called TP240 PhoneHome, created a tsunami of TCP flooding attacks, and rapidly expanded high-powered botnets to plague network-connected resources. In addition, bad actors have openly embraced online aggression with high-profile DDoS attack campaigns related to geopolitical unrest, which have had global implications."
Deployed in most of the world's ISPs, large data centers, and government and enterprise networks, NETSCOUT Arbor DDoS attack protection solutions send anonymized DDoS attack statistics to NETSCOUT's Active Level Threat Analysis System (ATLAS™). This data, which includes visibility into more than 190 countries, 550 industries, and 50,000 autonomous system numbers (ASNs), is then analyzed and curated by NETSCOUT's ATLAS Security Engineering and Response Team (ASERT) to provide unique insights in the report. No other vendor sees and knows more about DDoS attack activity and best practices in protection than NETSCOUT.
Key findings from the 1H2022 NETSCOUT DDoS Threat Intelligence Report include:
- There were 6,019,888 global DDoS attacks in 1st half of 2022.
- TCP-based flood attacks (SYN, ACK, RST) remain the most used attack vector, with approximately 46% of all attacks continuing a trend that started in early 2021.
- DNS water-torture attacks accelerated into 2022 with a 46% increase primarily using UDP query floods, while carpet-bombing attacks experienced a big comeback toward the end of the second quarter; overall, DNS amplification attacks decreased by 31% from 2H2021 to 1H2022.
- The new TP240 PhoneHome reflection/amplifications DDoS vector was discovered in early 2022 with a record-breaking amplification ratio of 4,293,967,296:1; swift actions eradicated the abusable nature of this service.
- Malware botnet proliferation grew at an alarming rate, with 21,226 nodes tracked in the first quarter to 488,381 nodes in the second, resulting in more direct-path, application-layer attacks.
Geopolitical Unrest Spawns Increased DDoS Attacks
As Russian ground troops entered Ukraine in late February, there was a significant uptick in DDoS attacks targeting governmental departments, online media organizations, financial firms, hosting providers, and cryptocurrency-related firms, as previously documented. However, the ripple effect resulting from the war had a dramatic impact on DDoS attacks in other countries too, including:
- Ireland experienced a surge in attacks after providing service to Ukrainian organizations.
- India experienced a measurable increase in DDoS attacks following its abstention from the UN Security Council and General Assembly votes condemning Russia's actions in Ukraine.
- On the same day, Taiwan endured its single-highest number of DDoS attacks after making public statements supporting Ukraine, as with Belize.
- Finland experienced a 258% increase in DDoS attacks year-over-year, coinciding with its announcement to apply for NATO membership.
- Poland, Romania, Lithuania, and Norway were targeted by DDoS attacks linked to Killnet; a group of online attackers aligned with Russia.
- While the frequency and severity of DDoS attacks in North America remained relatively consistent, satellite telecommunications providers experienced an increase in high-impact DDoS attacks, especially after providing support for Ukraine's communications infrastructure.
- Russia experienced a nearly 3X increase in daily DDoS attacks since the conflict with Ukraine began and continued through the end of the reporting period.
Similarly, as tensions between Taiwan, China, and Hong Kong escalated in 1H2022, DDoS attacks against Taiwan regularly occurred in concert with related public events.
NETSCOUT's DDoS Threat Intelligence Report covers the latest trends and activities in the DDoS threat landscape. It covers data captured from NETSCOUT's ATLAS and expert insights from ASERT.
The visibility and insights compiled from the global DDOS attack data, represented in the DDoS Threat Intelligence Report, and seen in the Omnis Threat Horizon portal, fuel the ATLAS Intelligence Feed (AIF). In addition, AIF continuously arms NETSCOUT's Omnis and Arbor security portfolio enabling them to automatically detect and block threat activity for enterprises and service providers worldwide.
Visit our interactive website for more information on NETSCOUT's semi-annual DDoS Threat Intelligence Report. You can also find us on Facebook, LinkedIn , and Twitter for threat updates and the latest trends and insights.
About NETSCOUT
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) protects the connected world from cyberattacks and performance disruptions through advanced network detection and response and pervasive network visibility. Powered by our pioneering deep packet inspection at scale, we serve the world's largest enterprises, service providers, and public sector organizations. Learn more at www.netscout.com or follow @NETSCOUT on LinkedIn, Twitter, or Facebook.
©2022 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220927005076/en/
Contact information
Editorial Contacts:
Maribel Lopez
Manager, Marketing & Corporate Communications
+1 781 362 4330
maribel.lopez@netscout.com
Chris Shattuck
Finn Partners for NETSCOUT
+1 678 504 6785
NETSCOUT-US@FinnPartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
